Asia-pacific Companion Diagnostics Market 2022-2028
MARKET OUTLOOK
Triton’s research report suggests that the Asia-Pacific companion diagnostics market is anticipated to showcase a CAGR of 13.10% during the forecasted years 2022-2028. China, India, Australia & New Zealand, Japan, ASEAN countries, South Korea, and Rest of Asia-Pacific are considered in the region.
India is considered a major emerging genomics market, with oncologists accepting biomarker-based tests. The rising middle-class healthcare facilities and skilled practitioners have driven the expansion of clinical diagnostics in the country. Besides this, government hospitals like AIIMS and NIMHANS are striving to identify new disease genes and biomarkers. Therefore, these factors are expected to fuel the development of the companion diagnostics market across India over the forecast period.
In South Korea, the public healthcare system is offered to all citizens through the National Health Insurance Corporation under the Ministry of Health and Wellness. As per WHO, the Ministry is in charge of policies and supervision of the healthcare systems. In this regard, the Health Insurance Review Agency reviews medical charges, evaluating the overall healthcare system. The overall development of the healthcare system supports the demand for companion diagnostics tests, driving the South Korean market’s growth.
COMPETITIVE OUTLOOK
The leading companies in the companion diagnostics market include Almac Group, Biocartis, Abbott Laboratories, Arup Laboratories, GE Healthcare, and Qiagen.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook